{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T23:26:32Z","timestamp":1789255592380,"version":"build-2803163510"},"reference-count":113,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.berh.2023.101858","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:49:40Z","timestamp":1693874980000},"page":"101858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Treatment overview of axial spondyloarthritis in 2023"],"prefix":"10.1016","volume":"37","author":[{"given":"X.","family":"Baraliakos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Kiltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Kononenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ciurea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2023.101858_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2023.101858_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/annrheumdis-2013-203582","article-title":"Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis","volume":"74","author":"Stolwijk","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib3","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13075-016-1093-z","article-title":"Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis","volume":"18","author":"de Winter","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2023.101858_bib4","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro S Nikiphorou","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib6","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/acr.24025","article-title":"Update of the American College of rheumatology\/spondylitis association of America\/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2023.101858_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis","volume":"68","author":"Lukas","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","article-title":"Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib10","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/annrheumdis-2020-219585","article-title":"Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial","volume":"80","author":"Molto","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/ar4561","article-title":"The window of opportunity: a relevant concept for axial spondyloarthritis","volume":"16","author":"Robinson","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2023.101858_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152032","article-title":"How is early spondyloarthritis defined in the literature? Results from a systematic review","volume":"55","author":"Benavent","year":"2022","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2023.101858_bib13","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/rheumatology\/keac532","article-title":"Treating spondyloarthritis early: does it matter? Results from a systematic literature review","volume":"62","author":"Capelusnik","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101858_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2023-eular.697","article-title":"ASAS consensus definition of early axial spondyloarthritis","author":"Navarro-Comp\u00e1n","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib15","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/art.33465","article-title":"Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis","volume":"64","author":"Poddubnyy","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2023.101858_bib16","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s10067-020-05319-6","article-title":"Influence of smoking and obesity on treatment response in patients with axial spondyloarthritis: a systematic literature review","volume":"40","author":"Zurita Prada","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2023.101858_bib17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/annrheumdis-2013-204055","article-title":"Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study","volume":"74","author":"Ramiro","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2023.101858_bib18","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1136\/annrheumdis-2014-205178","article-title":"Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/rheumatology\/keaa564","article-title":"Disease activity is associated with spinal radiographic progression in axial spondyloarthritis independently of exposure to tumour necrosis factor inhibitors","volume":"60","author":"Sepriano","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101858_bib20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/annrheumdis-2017-211544","article-title":"TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort","volume":"77","author":"Molnar","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib21","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1136\/annrheumdis-2018-213585","article-title":"EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis","volume":"77","author":"Rausch Osthoff","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2021-222020","article-title":"EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases","volume":"82","author":"Gwinnutt","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib23","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1186\/1471-2458-13-813","article-title":"Long-term health benefits of physical activity--a systematic review of longitudinal studies","volume":"13","author":"Reiner","year":"2013","journal-title":"BMC Publ Health"},{"key":"10.1016\/j.berh.2023.101858_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000397","article-title":"Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis","volume":"3","author":"Regel","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.berh.2023.101858_bib25","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/ard-2022-223297","article-title":"Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis","volume":"82","author":"Ortolan","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001480","article-title":"To move or not to move: the paradoxical effect of physical exercise in axial spondyloarthritis","volume":"7","author":"Perrotta","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.berh.2023.101858_bib27","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/bjsports-2018-099943","article-title":"High intensity exercise for 3 months reduces disease activity in axial spondyloarthritis (axSpA): a multicentre randomised trial of 100 patients","volume":"54","author":"Sveaas","year":"2020","journal-title":"Br J Sports Med"},{"key":"10.1016\/j.berh.2023.101858_bib28","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/acr.23705","article-title":"Barriers and facilitators of vigorous cardiorespiratory training in axial spondyloarthritis: surveys among patients, physiotherapists, and rheumatologists","volume":"71","author":"Niedermann","year":"2019","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2023.101858_bib29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/acr.24788","article-title":"Motivators, barriers, and opportunity for E-health to encourage physical activity in axial spondyloarthritis: a qualitative descriptive study","volume":"74","author":"Passalent","year":"2022","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2023.101858_bib30","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/art.41408","article-title":"Do smoking and socioeconomic factors influence imaging outcomes in axial spondyloarthritis? Five-year data from the DESIR cohort","volume":"72","author":"Nikiphorou","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2023.101858_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000153","article-title":"Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis","volume":"1","author":"Ramiro","year":"2015","journal-title":"RMD Open"},{"key":"10.1016\/j.berh.2023.101858_bib32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/rheumatology\/kew367","article-title":"Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis","volume":"56","author":"Baraliakos","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101858_bib33","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","article-title":"Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial","volume":"52","author":"Wanders","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2023.101858_bib34","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","article-title":"Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS)","volume":"75","author":"Sieper","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/annrheumdis-2022-eular.568","volume":"81","author":"Proft","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib36","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11926-023-01097-7","article-title":"Have Therapeutics enhanced Our Knowledge of axial spondyloarthritis?","volume":"25","author":"Harrison","year":"2023","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.berh.2023.101858_bib37","series-title":"TNF-alpha inhibitors for ankylosing spondylitis","first-page":"CD005468","author":"Maxwell","year":"2015"},{"key":"10.1016\/j.berh.2023.101858_bib38","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1136\/annrheumdis-2019-215427","article-title":"Treatment response and drug retention rates in 24 195 biologic-na\u00efve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration","volume":"78","author":"\u00d8rnbjerg","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib39","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1093\/rheumatology\/keab945","article-title":"European bio-na\u00efve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response","volume":"61","author":"Christiansen","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101858_bib40","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/art.24408","article-title":"Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis","volume":"60","author":"Barkham","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2023.101858_bib41","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/art.21790","article-title":"Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study","volume":"54","author":"Braun","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2023.101858_bib42","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","article-title":"The impact of tumor necrosis factor \u03b1 inhibitors on radiographic progression in ankylosing spondylitis","volume":"65","author":"Haroon","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2023.101858_bib43","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jbspin.2015.09.006","article-title":"Radiographic progression in patients with ankylosing spondylitis according to tumor necrosis factor blocker exposure: observation Study of Korean Spondyloarthropathy Registry (OSKAR) data","volume":"83","author":"Kim","year":"2016","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.berh.2023.101858_bib44","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/acr.23097","article-title":"Reduction in spinal radiographic progression in ankylosing spondylitis patients receiving prolonged treatment with tumor necrosis factor inhibitors","volume":"69","author":"Maas","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2023.101858_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168958","article-title":"Impact of dose tapering of tumor necrosis factor inhibitor on radiographic progression in ankylosing spondylitis","volume":"11","author":"Park","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.berh.2023.101858_bib46","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/art.41667","article-title":"Tumor necrosis factor inhibitors reduce spinal radiographic progression in patients with radiographic axial spondyloarthritis: a longitudinal analysis from the Alberta prospective cohort","volume":"73","author":"Sepriano","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2023.101858_bib47","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13075-023-03026-6","article-title":"Site-specific assessment of spinal radiographic progression improves detection of TNF blocker-associated disease modification in axial spondyloarthritis: longitudinal observational data from the Swiss Clinical Quality Management Registry","volume":"25","author":"Popova","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2023.101858_bib48","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/art.41206","article-title":"Effect of therapy on radiographic progression in axial spondyloarthritis: a systematic review and meta-analysis","volume":"72","author":"Karmacharya","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2023.101858_bib49","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/art.42144","article-title":"Treatment with tumor necrosis factor inhibitors is associated with a time-shifted retardation of radiographic sacroiliitis progression in patients with axial spondyloarthritis: 10-year results from the German spondyloarthritis inception cohort","volume":"74","author":"Torgutalp","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2023.101858_bib50","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1136\/annrheumdis-2017-212008","article-title":"Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis","volume":"77","author":"Dougados","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib51","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.semarthrit.2017.04.005","article-title":"Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis","volume":"47","author":"Deodhar","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2023.101858_bib52","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3389\/fimmu.2020.00312","article-title":"Immunogenicity of TNF-inhibitors","volume":"11","author":"Atiqi","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2023.101858_bib53","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3389\/fimmu.2019.00382","article-title":"Anti-TNF therapy in spondyloarthritis and related diseases, impact on the immune system and prediction of treatment responses","volume":"10","author":"Menegatti","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2023.101858_bib54","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1136\/annrheumdis-2013-205133","article-title":"Impaired response to treatment with tumour necrosis factor \u03b1 inhibitors in smokers with axial spondyloarthritis","volume":"75","author":"Ciurea","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib55","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1093\/rheumatology\/keab242","article-title":"Depression and anxiety symptoms at TNF inhibitor initiation are associated with impaired treatment response in axial spondyloarthritis","volume":"60","author":"Zhao","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101858_bib56","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1093\/rheumatology\/key206","article-title":"Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national register","volume":"57","author":"Macfarlane","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101858_bib57","first-page":"62","article-title":"Smoking and high BMI are associated with reductions in TNF inhibitor response in psoriatic arthritis: results from 12 European countries","author":"Jones","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101858_bib58","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13075-017-1372-3","article-title":"Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis","volume":"19","author":"Micheroli","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2023.101858_bib59","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3389\/fphar.2019.00047","article-title":"Sex differences in response to TNF-inhibiting drugs in patients with spondyloarthropathies or inflammatory bowel diseases","volume":"10","author":"Lagan\u00e0","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.berh.2023.101858_bib60","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3899\/jrheum.17666","article-title":"The sex influence on response to tumor necrosis factor-\u03b1 inhibitors and remission in axial spondyloarthritis","volume":"45","author":"Lubrano","year":"2018","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2023.101858_bib61","doi-asserted-by":"crossref","first-page":"961","DOI":"10.55563\/clinexprheumatol\/dz0xrd","article-title":"Quality of life and therapeutic management of axial spondyloarthritis patients in Italy: a 12-month prospective observational study","volume":"39","author":"D'Angelo","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2023.101858_bib62","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1136\/annrheumdis-2012-202431","article-title":"Female patients with ankylosing spondylitis: analysis of the impact of gender across treatment studies","volume":"72","author":"van der Horst-Bruinsma","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib63","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1080\/03009742.2021.1967046","article-title":"Disease activity in women with ankylosing spondylitis remains higher under Tumour Necrosis Factor inhibitor treatment than in men: a five-year observational study","volume":"51","author":"Rusman","year":"2022","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.berh.2023.101858_bib64","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s13075-020-02337-2","article-title":"Differences between men and women with nonradiographic axial spondyloarthritis: clinical characteristics and treatment effectiveness in a real-life prospective cohort","volume":"22","author":"Neuenschwander","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2023.101858_bib65","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3899\/jrheum.170166","article-title":"Response to tumor necrosis factor inhibition in male and female patients with ankylosing spondylitis: data from a Swiss cohort","volume":"45","author":"Hebeisen","year":"2018","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2023.101858_bib66","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/ard.2010.131797","article-title":"Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register","volume":"70","author":"Lie","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib67","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000524","article-title":"Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review","volume":"3","author":"Navarro-Comp\u00e1n","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.berh.2023.101858_bib68","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13075-020-02288-8","article-title":"Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant?","volume":"22","author":"Manica","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2023.101858_bib69","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13075-016-0969-2","article-title":"Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort","volume":"18","author":"Ciurea","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2023.101858_bib70","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13075-020-02208-w","article-title":"Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-analysis","volume":"22","author":"Yin","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2023.101858_bib71","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1093\/rheumatology\/keaa268","article-title":"Effect of biologic disease-modifying anti-rheumatic drugs targeting remission in axial spondyloarthritis: systematic review and meta-analysis","volume":"59","author":"Cruz-Machado","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101858_bib72","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.40753","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2023.101858_bib73","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001280","article-title":"Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration","volume":"6","author":"Michelsen","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.berh.2023.101858_bib74","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1136\/annrheumdis-2019-215934","article-title":"Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort","volume":"79","author":"Micheroli","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib75","doi-asserted-by":"crossref","first-page":"5743","DOI":"10.1093\/rheumatology\/keab245","article-title":"Retention rate and effectiveness of secukinumab vs TNF inhibitor in ankylosing spondylitis patients with prior TNF inhibitor exposure","volume":"60","author":"Min","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101858_bib76","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/acr.24523","article-title":"One-year treatment outcomes of secukinumab versus tumor necrosis factor inhibitors in spondyloarthritis: results from five nordic biologic registries including more than 10,000 treatment courses","volume":"74","author":"Glintborg","year":"2022","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2023.101858_bib77","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/ard-2022-223595","article-title":"Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials","volume":"82","author":"van der Heijde","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib78","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/annrheumdis-2023-eular.301","article-title":"Effect of secukinumab versus adalimumab biosimilar on radiographic progression in patients with radiographic axial spondyloarthritis: a randomized phase IIIb study","volume":"82","author":"Baraliakos","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib79","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib80","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","article-title":"Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Deodhar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2023.101858_bib81","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2023.101858_bib82","doi-asserted-by":"crossref","first-page":"R439","DOI":"10.1186\/ar1693","article-title":"Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab","volume":"7","author":"Baraliakos","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2023.101858_bib83","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/ard-2022-223298","article-title":"Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis","volume":"82","author":"Webers","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib84","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/rheumatology\/kew033","article-title":"Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review","volume":"55","author":"Navarro-Comp\u00e1n","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101858_bib85","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1080\/14397595.2021.1878985","article-title":"The risk factors and incidence of major infectious diseases in patients with ankylosing spondylitis receiving tumor necrosis factor inhibitors","volume":"31","author":"Koo","year":"2021","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.berh.2023.101858_bib86","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20929208","article-title":"Factors associated with sepsis risk in immune-mediated inflammatory diseases receiving tumor necrosis factor inhibitors: a nationwide study","volume":"12","author":"Chao","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.berh.2023.101858_bib87","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/annrheumdis-2016-209270","article-title":"Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers","volume":"76","author":"Hellgren","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib88","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s41927-022-00275-x","article-title":"Malignancy in ankylosing spondylitis: a cross-sectional analysis of a large population database","volume":"6","author":"Bittar","year":"2022","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.berh.2023.101858_bib89","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/annrheumdis-2019-216693","article-title":"Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden","volume":"79","author":"Kopp","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib90","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/art.41911","article-title":"Safety and efficacy of upadacitinib in patients with active ankylosing spondylitis and an inadequate response to nonsteroidal antiinflammatory drug therapy: one-year results of a double-blind, placebo-controlled study and open-label extension","volume":"74","author":"Deodhar","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2023.101858_bib91","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2023.101858_bib92","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/1756-185X.14485","article-title":"Management of extra-articular manifestations in spondyloarthritis","volume":"26","author":"Ma","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib93","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2023.101858_bib94","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/annrheumdis-2021-220420","article-title":"Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?","volume":"80","author":"Lindstr\u00f6m","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib95","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.berh.2023.101858_bib96","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.berh.2023.101858_bib97","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2023.101858_bib98","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.berh.2023.101858_bib99","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2023.101858_bib100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjw133","article-title":"Pharmacokinetics and exposure-response relationship of golimumab in patients with moderately-to-severely active ulcerative colitis: results from phase 2\/3 PURSUIT induction and maintenance studies","volume":"11","author":"Adedokun","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.berh.2023.101858_bib101","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","article-title":"Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials","volume":"78","author":"Schreiber","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib102","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A\u00a0head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib103","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2023.101858_bib104","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002067","article-title":"Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observational cohort","volume":"8","author":"Ciurea","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.berh.2023.101858_bib105","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s13075-021-02613-9","article-title":"Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT","volume":"23","author":"Braun","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2023.101858_bib106","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004800.pub3","article-title":"Sulfasalazine for ankylosing spondylitis","author":"Chen","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.berh.2023.101858_bib107","article-title":"Methotrexate for ankylosing spondylitis","volume":"2","author":"Chen","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.berh.2023.101858_bib108","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1093\/rheumatology\/keac174","article-title":"The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis","volume":"61","author":"Nissen","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101858_bib109","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/annrheumdis-2012-203055","article-title":"Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial","volume":"73","author":"Haibel","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101858_bib110","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/rheumatology\/keaa685","article-title":"Efficacy of a step-down regimen of oral prednisolone in axial spondyloarthritis: result of a double-blind randomized controlled trial (COBRA-AS Study)","volume":"60","author":"Mishra","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101858_bib111","first-page":"74","article-title":"Opioid use and healthcare utilization in adults with PsA and AS [abstract]","author":"Ogdie","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2023.101858_bib112","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4055\/cios.2017.9.3.263","article-title":"Comparison of outcomes of total hip arthroplasty between patients with ankylosing spondylitis and avascular necrosis of the femoral head","volume":"9","author":"Lee","year":"2017","journal-title":"Clin Orthop Surg"},{"key":"10.1016\/j.berh.2023.101858_bib113","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13018-019-1170-5","article-title":"Comparison of loss of correction between PSO and VCD technique in treating thoracolumbar kyphosis secondary to ankylosing spondylitis, a minimum 2 years follow-up","volume":"14","author":"Wang","year":"2019","journal-title":"J\u00a0Orthop Surg Res"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169422300044X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169422300044X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:23:46Z","timestamp":1761499426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169422300044X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":113,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S152169422300044X"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2023.101858","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment overview of axial spondyloarthritis in 2023","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2023.101858","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101858"}}